Antibodies to neutralize broad range of Dengue virus strains discovered

0
813

Dengue is a mosquito-borne viral infection, with an estimated 400 million infections occurring annually. It affects millions of people throughout the world and in severe cases, can prove fatal. Dengue is common in Singapore too and the government takes extra measures to contain mosquitoes and actively spreads education about dengue fever to the residents of the country. Hence, the discovery by scientists on a new class of highly potent, neutralizing antibodies against various strains of dengue virus is cutting edge. The study was published in the highly acclaimed journal, Nature Immunology, on 15th December 2014. The scientists have discovered a previously unknown epitope, the envelope dimer epitope (EDE). The study characterized 145 monoclonal antibodies and found that the antibodies specific to EDEs were reactive broadly across various dengue complexes. This research can be used to engineer a highly effective vaccine in the near future.

To access the original article, please read at: http://www.nature.com/ni/journal/vaop/ncurrent/full/ni.3058.html#affil-auth Disclaimer: This article does not reflect any personal views of the authors/editors.

Previous articleAbility to stand on one leg is a sign of brain health
Next articleMed Tech: A*STAR and GE Healthcare collaboration
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (www.sciglo.com); -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo (www.sciglo.com) and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.